

FDA Assigns Priority Review Status for Sanofi Aventis' Multaq

The priority review is granted to applications in which a new indication or new drug product, if approved, has a potential to present a safe and effective therapy where no satisfactory alternative exists compared to currently available therapies or marketed products. A registration dossier is also under regulatory review by the European Medicines Agency (EMA) for a Marketing Authorization Application.

Published on : Mon, 25 Aug 2008